Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05780749
Other study ID # BK-IBS-2301
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 23, 2023
Est. completion date December 15, 2024

Study information

Verified date January 2024
Source Biokuris s.a.
Contact Salvatore Modica
Phone +32 4 259 85 00
Email s.modica@biokuris.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Irritable Bowel Syndrome (IBS) is a common chronic gastrointestinal condition that affects approximately 10-20% of adults in Western countries. IBS is a disorder with chronic or recurrent colonic symptoms without a clear-cut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION. Symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. Over 80% of individuals with IBS report food-related symptoms leading in the 70% of these patients to self-imposed food restrictions and/or modifications of their diet. These spontaneous unsupervised dietary modifications are associated with maladaptive eating patterns and unnecessary self-restricted diets, which could result in nutritional deficiencies. BiOkuris product DDI-IBS-001 is a food multicomponents product based on BiOkuris proprietary chitin-glucan complex. The objectives of the VITABIOTIC study is to confirm the effectiveness of the DDI-IBS-001 product in improving global symptoms, abdominal pain, stool consistency, quality of life, anxiety and depression in IBS patients and to confirm the product's safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 130
Est. completion date December 15, 2024
Est. primary completion date December 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Adult females and males, aged 18-75 years, 2. Diagnosis of IBS at least 6 months prior to study entry, 3. Confirmed IBS according to Rome-IV criteria (as determined by investigator), 4. Patient having either constipation (IBS-C), diarrhoea (IBS-D) or alternance of constipation/diarrhoea (IBS-M), 5. Possession of a digital device (i.e., smartphone or tablet), 6. Patient who read, understood, and signed the informed consent form (ICF), 7. Patient willing to adhere to the study visit schedule and capable to understand and comply with protocol requirements and product intake, 8. Male, or female patient of childbearing potential, who agrees to use acceptable birth control methods throughout the study period. As assessed at the end of the run-in period, week 2 : 9. Patient with a baseline score for abdominal pain = 2 and < 6 assessed on a 7-point Lickert scale 10. Patient with correct and complete reporting of the study questionnaires and scores during the run-in period (=75% completion) Exclusion Criteria: 1. Severe gastrointestinal pathologies other than IBS, including: ulcers, coeliac disease, inflammatory bowel disease, bowel cancer, bowel resection, auto-immune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Graves' disease), bariatric surgery, acute or chronic diarrhoea secondary to confirmed infectious gastroenteritis, or enteral or parenteral nutrition, 2. Metabolic disorders affecting intestinal transit function or nutrient absorption including uncontrolled diabetes and uncontrolled dysthyroidism, 3. Patients experiencing complications of abdominal radiotherapy, 4. Surgical operations to the mouth or gastrointestinal tract within 4 weeks prior to study entry, or planned during the study; appendectomy within 6 months prior to study entry, 5. Galactose intolerance , 6. Use of opioids or narcotic analgesics within 6 weeks prior to week 0, 7. Systemic antibiotic treatment in progress or prescribed less than 4 weeks prior to study entry, 8. Use of products marketed as or rich in prebiotics, probiotics, or symbiotics (e.g., kefir, probiotic yogurt, baker's yeast, etc.) less than 2 weeks prior to week 0, 9. Use of laxatives, antibloating agents, antidiarrheal medication, antispasmodics, anxiolytics, antidepressants, analgesics, and non-steroidals anti-inflammatory drugs if started less than 2 months prior to week 0 . These medications are authorized if consumed for longer than 2 months before week 0 and maintained at a stable dosage for the entire study duration,, 10. Diets including low-FODMAP, KETO/high-fat, gluten free/coeliac, paleo, weight loss, caloric restriction, low-carb, 5:2/whole day energy restriction, Atkins/high-protein, sugar-free, single-food, juicing/any day of juicing, any other restriction diet (e.g. very low calory), or vegan diets if started less than 2 months prior or stopped less than 1 month prior to week 0. These diets are authorized if followed for longer than 2 months before week 0 and maintained for the entire study duration,, 11. Excessive alcohol consumption (more than 10 units per week) and/or drug abuse, 12. Pregnancy and lactation, or plan to become pregnant during the study period, 13. Participation in other studies involving investigational or marketed products concomitantly or less than 3 months prior to study entry, 14. Known hypersensitivity to any of the ingredients or excipients of the investigational products, 15. Patient who has forfeited their freedom by administrative or legal award, or who is under guardianship or under limited judicial protection. As assessed at the end of the run-in period, week 2 : 16. Use of opioids or narcotic analgesics during the run-in period (between week 0 and week 1), 17. Systemic antibiotic treatment in progress or prescribed during the run-in period (between week 0 and week 1), 18. Deviation from lifestyle and dietary recommendations to be followed during the study (between week 0 and week 1).

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
DDI-IBS-001
The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.
Other:
DDDI-IBS-001 placebo
The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.

Locations

Country Name City State
Belgium Centre Hospitalier EpiCURA Ath
Belgium AZ Sint-Jan Brugge
Belgium AZ Sint-Lucas Brugge
Belgium Cliniques Universitaires Saint-Luc Bruxelles
Belgium CUB Hôpital Erasme Bruxelles
Belgium AZ Sint-Lucas Gent
Belgium UZ Brussel Jette
Belgium UZ Leuven Leuven
Belgium CHU Liege Liege
Belgium Clinique CHC Mont-Legia Liege
Belgium Centre Hospitalier du Bois de l'Abbaye Seraing

Sponsors (1)

Lead Sponsor Collaborator
Biokuris s.a.

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Symptoms global assessment of relief (SGA) responder rate The primary outcome is the subjective global assessment (SGA) of relief responder rate at Week 8. Patients with an SGA of relief score of 3 points or less each week will be considered weekly responders. Patients who respond weekly for at least 50% of assessments after 2 weeks of Biokuris food supplement administration until V3 will be considered overall responders. Week 10 (8 weeks after run-in period)
Secondary Weekly SGA responder rate The SGA of relief weekly responder rate after 8 weeks of Biokuris food supplement administration. Patients with an SGA of relief score of 3 points or less each week will be considered weekly responders. weekly from week 2 to week 14
Secondary Individual symptoms Weekly change from baseline in mean 7-point Likert scale for each of the symptoms: abdominal pain, abdominal bloating, flatulence, dyschezia, pain during evacuation. Patients will score the intensity of each symptom individually from 1 (none) to 7 (very severe). Incidence of responders. weekly from week 2 to week 14
Secondary stool consistency Change in the weekly mean number of normal stool consistency, evaluated with the BSS. Stool consistency (BSS score) will be described for each week until V4. The change in the weekly average number of normal stool consistency will be calculated between week 2 (baseline), and each week of treatment weekly from week 2 to week 14
Secondary number of evacuation per day Change in the weekly mean number of evacuations per day. The mean daily number of bowel movements will be calculated for each week until week 14. The change in the weekly average number of evacuations will be calculated between week 2 (baseline), and each week of treatment, until week 14. A stratification will be performed according to weekly mean numbers registered at week 2. weekly from week 2 to week 14
Secondary IBS-QoL Absolute and relative change of IBS-QoL (Quality of Life) score. An analysis for each of the 8 domains of the validated questionnaire will be performed. Week 0, week 4, week 8, week 10, week 14
Secondary Anxiety & Depression Monthly change from baseline in Hospitalization Anxiety and Depression Scale (HADS) score. It is divided into an anxiety subscale (HADS-A) and a depression subscale (HADS-D), both containing 7 intermingled items, and are scored separately. For both scales, scores of less than 7 indicate non-cases, and between 8-10 mild, 11-14 moderate and 15-21 severe symptomatology. Week 0, week 4, week 8, week 10, week 14
Secondary Adverse events occurrence and severity of adverse events Week 0, week 2, week 4, week 8, week 10, week 14
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3